분자영상 및 방사화학

본문글자크기
  • [J Control Release.] Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model.

    [J Control Release.] Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model.

    한양대 / 윤아름, 윤채옥*

  • 출처
    J Control Release.
  • 등재일
    2016 Jun 10
  • 저널이슈번호
    231:2-16. doi: 10.1016/j.jconrel.2016.02.046. Epub 2016 Mar 4.
  • 내용

    바로가기  >


    Abstract

    Adenovirus (Ad)-mediated cancer gene therapy has been proposed as a promising alternative to conventional therapy for cancer. However, success of systemically administered naked Ad has been limited due to the immunogenicity of Ad and the induction of hepatotoxicity caused by Ad's native tropism. In this study, we synthesized an epidermal growth factor receptor (EGFR)-specific therapeutic antibody (ErbB)-conjugated and PEGylated poly(amidoamine) (PAMAM) dendrimer (PPE) for complexation with Ad. Transduction of Ad was inhibited by complexation with PEGylated PAMAM (PP) dendrimer due to steric hindrance. However, PPE-complexed Ad selectively internalized into EGFR-positive cells with greater efficacy than either naked Ad or Ad complexed with PP. Systemically administered PPE-complexed oncolytic Ad elicited significantly reduced immunogenicity, nonspecific liver sequestration, and hepatotoxicity than naked Ad. Furthermore, PPE-complexed oncolytic Ad demonstrated prolonged blood retention time, enhanced intratumoral accumulation of Ad, and potent therapeutic efficacy in EGFR-positive orthotopic lung tumors in comparison with naked Ad. We conclude that ErbB-conjugated and PEGylated PAMAM dendrimer can efficiently mask Ad's capsid and retarget oncolytic Ad to be efficiently internalized into EGFR-positive tumor while attenuating toxicity induced by systemic administration of naked oncolytic Ad. 

     

     

    Author information

    Yoon AR1, Kasala D1, Li Y1, Hong J1, Lee W1, Jung SJ1, Yun CO2.

    1Department of Bioengineering, College of Engineering, Hanyang University, South Korea.

    2Department of Bioengineering, College of Engineering, Hanyang University, South Korea. Electronic address: chaeok@hanyang.ac.kr. 

  • 키워드
    Adenovirus; Cancer; Cetuximab; Decorin; Dendrimer; EGFR; Erbitux; Gene therapy; Oncolytic adenovirus; PAMAM; PEGylation; c-Met; shRNA
  • 연구소개
    본 연구는 epidermal growth factor receptor (EGFR)의 특이적 항체(ErbB)가 결합되고 PEG에 의해 코팅된 형태의 고분자 poly(amidoamine) (PAMAM) dendrimer (PPE)를 아데노바이러스와 결합하여 전신투여 함으로서 바이러스 구조단백질에 의한 독성을 감소시키고, 혈액 내 잔류시간 연장과 종양 내 바이러스 축적량 증가를 통해 폐암 동소이식모델에서 항종양 효과를 크게 증진시켰습니다. 이러한 연구결과는 고분자 (PPE)와 결합된 아데노바이러스가 효과적으로 아데노바이러스의 구조 단백질을 코팅하고 암세포 표적효율을 증가 시켜 아데노바이러스의 독성은 최소화하고 항종양 효과는 극대화 할 수 있는 신개념의 항암치료제로 이용될 것을 기대할 수 있습니다.
  • 덧글달기
    덧글달기
       IP : 13.58.121.131

    등록